Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$1.00 USD
-0.05 (-4.76%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $0.99 -0.01 (-1.00%) 6:00 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GOSS 1.00 -0.05(-4.76%)
Will GOSS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GOSS
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Other News for GOSS
Bullish Outlook on Gossamer Bio’s Seralutinib Efficacy and Market Potential
Gossamer Bio (GOSS) Receives a Buy from Oppenheimer
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
Closing Bell Movers: Apple down slightly on CFO change; Trip.com up on earnings